On average, it takes nearly six years for people with Lupus to be diagnosed from the time they notice their first symptoms. May is Lupus Awareness month, and Dr. Amrie Grammer, co-founder of Ampel...
Virginia Based AMPEL BioSolutions’ Machine Learning Breakthrough Predicts Chronic Disease Flares From A Blood Sample
CLICK TO READ THE ARTICLE > CHARLOTTESVILLE, Va., July 9, 2019 /PRNewswire/ -- AMPEL BioSolutions today announces a breakthrough in precision and personalized medicine that could revolutionize...
Alterations in Macrophage Activation May Signal a Lupus Flare
By Lara C. Pullen, PhD CLICK TO VIEW ARTICLE > Rheumatologists lack a definitive diagnostic tool to determine whether a patient has systemic lupus erythematous (SLE) and/or when a patient will...
The state of lupus treatments and what the future looks like.
Les Sinclair talks with Dr. Amrie Grammer about AMPEL BioSolutions, a Charlottesville Virginia company that has reengineered the gene-based technology they developed for lupus to COVID19.
Data mining could lead to therapy advances
Peter E. Lipsky, MD, Co-Founder and Chief Executive Officer of AMPEL BioSolutions, Charlottesville, VA, works to change that, and he will discuss his efforts during the Clinical Science symposium Mining Big Data for Drug Repurposing.